- Home
- TLSI vs GLSI Comparison
TLSI vs GLSI Comparison
Compare TLSI & GLSI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TLSI
- GLSI
- Stock Information
- Founded
- TLSI 2010
- GLSI 2006
- Country
- TLSI United States
- GLSI United States
- Employees
- TLSI N/A
- GLSI N/A
- Industry
- TLSI Medical Specialities
- GLSI Biotechnology: Pharmaceutical Preparations
- Sector
- TLSI Health Care
- GLSI Health Care
- Exchange
- TLSI Nasdaq
- GLSI Nasdaq
- Market Cap
- TLSI 150.0M
- GLSI 134.6M
- IPO Year
- TLSI N/A
- GLSI 2020
- Fundamental
- Price
- TLSI $3.94
- GLSI $12.01
- Analyst Decision
- TLSI Strong Buy
- GLSI Strong Buy
- Analyst Count
- TLSI 5
- GLSI 1
- Target Price
- TLSI $10.90
- GLSI $39.00
- AVG Volume (30 Days)
- TLSI 73.5K
- GLSI 67.3K
- Earning Date
- TLSI 08-12-2025
- GLSI 08-26-2025
- Dividend Yield
- TLSI N/A
- GLSI N/A
- EPS Growth
- TLSI N/A
- GLSI N/A
- EPS
- TLSI N/A
- GLSI N/A
- Revenue
- TLSI $35,990,000.00
- GLSI N/A
- Revenue This Year
- TLSI $55.39
- GLSI N/A
- Revenue Next Year
- TLSI $54.89
- GLSI N/A
- P/E Ratio
- TLSI N/A
- GLSI N/A
- Revenue Growth
- TLSI 45.50
- GLSI N/A
- 52 Week Low
- TLSI $3.42
- GLSI $8.06
- 52 Week High
- TLSI $6.04
- GLSI $16.50
- Technical
- Relative Strength Index (RSI)
- TLSI 39.84
- GLSI 57.66
- Support Level
- TLSI $3.42
- GLSI $11.44
- Resistance Level
- TLSI $4.00
- GLSI $12.83
- Average True Range (ATR)
- TLSI 0.36
- GLSI 0.66
- MACD
- TLSI -0.01
- GLSI -0.01
- Stochastic Oscillator
- TLSI 34.75
- GLSI 64.07
About TLSI TriSalus Life Sciences Inc.
TriSalus Life Sciences Inc is engaged in the research, development, and sales of drug delivery technology and immune-oncology therapeutics to improve outcomes in difficult-to-treat liver and pancreatic cancer. It is developing and marketing two product linesPressure Enabled Drug Delivery (PEDD) infusion systems, in use today, and an investigational agent, nelitolimod (SD-101), which shows potential to enhance immune system response in the treatment of hepatocellular cancer, pancreatic cancer and other liver solid tumors. TriNav is the newest therapy delivery device with SmartValve technology for the proprietary PEDD approach.
About GLSI Greenwich LifeSciences Inc.
Greenwich LifeSciences Inc a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, Flamingo-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences. GP2 is a 9 amino acid transmembrane peptide of the HER2/neu protein, a cell surface receptor protein that is expressed in a variety of common cancers, including expression in 75 percent of breast cancers at low (1+), intermediate (2+), and high (3+ or over-expressor) levels. The combination of GP2 + GM-CSF is called GLSI-100. The company is currently expanding Flamingo-01 into Europe with plans to open up to 150 sites globally.